Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking.
Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking.
复制标题
DOI：
10.1111/adb.12207
复制
发表时间：
2016-03
影响因子：
3.4
通讯作者：
Pond T
中科院分区：
文献类型：
--
作者：
Kranzler HR;Armeli S;Wetherill R;Feinn R;Tennen H;Gelernter J;Covault J;Pond T
先前的研究表明，托吡酯减少了酗酒者的饮酒量，一项研究表明，这种效果受到GRIK1基因(编码GluK1海人酸亚单位的基因)的多态性(Rs2832407)的影响。我们研究了药物和基因的交互作用是否(A)改变了日常自我效能感和以后饮酒之间的联系，以及(B)通过自我效能感间接影响饮酒。在托吡酯为期12周的安慰剂对照试验中，我们使用日常互动语音反应技术来测量122名欧美重度饮酒者的自我效能感(即避免当天晚些时候大量饮酒的信心)和饮酒行为。托吡酯对自我效能感和饮酒水平的影响被rs2832407缓和。在为期12周的试验中，接受托吡酯治疗的C等位基因纯合子显示出更高的自我效能感水平和更低的夜间饮酒水平。此外，托吡酯和基因对平均夜间饮酒水平的交互作用是通过平均自我效能水平来调节的。通过对托吡酯对夜间饮酒影响的多层次分析建模，我们发现自我效能感是一个关键的心理结构，对托吡酯的影响起到中介作用，并受rs2832407基因的调节。因此，有可能使用个体化评估(即，基因型)来选择治疗(即，旨在提高自我效能的托吡酯或心理疗法)，以优化减少大量饮酒，以提供个性化的治疗方法。
Previous studies indicate that topiramate reduces alcohol use among problem drinkers, with one study showing that the effect was moderated by a polymorphism (rs2832407) in GRIK1, the gene encoding the GluK1 kainate subunit. We examined whether the interactive effect of medication and genotype (a) altered the association between daily self-efficacy and later day drinking and (b) had an indirect effect on drinking via self-efficacy. In a 12-week, placebo-controlled trial of topiramate, we used daily interactive voice response technology to measure self-efficacy (i.e., confidence in avoiding heavy drinking later in the day) and drinking behavior in 122 European-American heavy drinkers. Topiramate’s effects on both self-efficacy and drinking level were moderated by rs2832407. C-allele homozygotes treated with topiramate showed higher levels of self-efficacy and lower levels of nighttime drinking across the 12-week trial. Further, the interactive effect of topiramate and genotype on mean nighttime drinking levels was mediated by mean levels of self-efficacy. By modeling topiramate’s effects on nighttime drinking across multiple levels of analysis, we found that self-efficacy, a key psychological construct, mediated the effect of topiramate, which was moderated by rs2832407 genotype. Thus, it may be possible to use an individualized assessment (i.e., genotype) to select treatment (i.e., topiramate or psychotherapy aimed at enhancing self-efficacy) to optimize the reduction in heavy drinking to provide a personalized treatment approach.
登录
查看更多内容
DOI：
10.1073/pnas.0910986107
发表时间：
2010-01-05
影响因子：
11.1
作者：
Birgner, Carolina;Nordenankar, Karin;Wallen-Mackenzie, Asa
通讯作者：
Wallen-Mackenzie, Asa
影响因子：
3.4
作者：
Kuerbis, Alexis;Armeli, Stephen;Morgenstern, Jon
通讯作者：
Morgenstern, Jon
影响因子：
2.3
作者：
Kranzler, Henry R.;Armeli, Stephen;Covault, Jonathan
通讯作者：
Covault, Jonathan
影响因子：
3.7
作者：
Schaumberg, Katherine;Kuerbis, Alexis;Muench, Frederick
通讯作者：
Muench, Frederick
影响因子：
--
作者：
BECK, AT;ERBAUGH, J;MENDELSOHN, M
通讯作者：
MENDELSOHN, M